COVID-19 and chronic rhinosinusitis : management and comorbidity - what have we learned?
INTRODUCTION: Approximately 5%-12% of the population worldwide suffer from chronic rhinosinusitis (CRS). CRS is defined as a chronic respiratory disease and is considered to be a risk factor for COVID-19 patients.
AREAS COVERED: A non-systematic literature research was conducted on COVID-19 and treatment options for CRSwNP. The latest international publications in medical databases, international guidelines, and the internet were reviewed. Since there were no publications on all aspects of this topic during the pandemic, we included our own experience in this report. Based on the conducted literature research in addition to our previously reported experience, we discuss the treatment of CRSwNP during the COVID-19 pandemic and what can be taken for future pandemics.
EXPERT OPINION: Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Indications for surgical treatment of CRS should be critically evaluated and reserved for patients with complications and those with no other treatment options. For this purpose, COVID-19 status should be known if possible and, in case of unclear status (emergency), using appropriate personal protective equipment. Systemic corticosteroids should be avoided were possible. Biological treatment should be continued under careful monitoring in uninfected patients and should be temporarily interrupted during COVID-19 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Expert review of clinical immunology - 19(2023), 11 vom: 08. Juli, Seite 1399-1406 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klimek, L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACE2 receptor expression |
|---|
| Anmerkungen: |
Date Revised 24.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/1744666X.2023.2244673 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360513956 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360513956 | ||
| 003 | DE-627 | ||
| 005 | 20231226083156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1744666X.2023.2244673 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360513956 | ||
| 035 | |a (NLM)37551742 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klimek, L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and chronic rhinosinusitis |b management and comorbidity - what have we learned? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a INTRODUCTION: Approximately 5%-12% of the population worldwide suffer from chronic rhinosinusitis (CRS). CRS is defined as a chronic respiratory disease and is considered to be a risk factor for COVID-19 patients | ||
| 520 | |a AREAS COVERED: A non-systematic literature research was conducted on COVID-19 and treatment options for CRSwNP. The latest international publications in medical databases, international guidelines, and the internet were reviewed. Since there were no publications on all aspects of this topic during the pandemic, we included our own experience in this report. Based on the conducted literature research in addition to our previously reported experience, we discuss the treatment of CRSwNP during the COVID-19 pandemic and what can be taken for future pandemics | ||
| 520 | |a EXPERT OPINION: Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Indications for surgical treatment of CRS should be critically evaluated and reserved for patients with complications and those with no other treatment options. For this purpose, COVID-19 status should be known if possible and, in case of unclear status (emergency), using appropriate personal protective equipment. Systemic corticosteroids should be avoided were possible. Biological treatment should be continued under careful monitoring in uninfected patients and should be temporarily interrupted during COVID-19 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACE2 receptor expression | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a CRSwNP | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a chronic rhinosinusitis | |
| 650 | 4 | |a intranasal corticosteroids | |
| 650 | 4 | |a nasal polyps | |
| 700 | 1 | |a Hagemann, J |e verfasserin |4 aut | |
| 700 | 1 | |a Huppertz, T |e verfasserin |4 aut | |
| 700 | 1 | |a Bärhold, F |e verfasserin |4 aut | |
| 700 | 1 | |a Albrecht, T |e verfasserin |4 aut | |
| 700 | 1 | |a Klimek, F |e verfasserin |4 aut | |
| 700 | 1 | |a Casper, I |e verfasserin |4 aut | |
| 700 | 1 | |a Cuevas, M |e verfasserin |4 aut | |
| 700 | 1 | |a Bergmann, C |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of clinical immunology |d 2005 |g 19(2023), 11 vom: 08. Juli, Seite 1399-1406 |w (DE-627)NLM191372153 |x 1744-8409 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:11 |g day:08 |g month:07 |g pages:1399-1406 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1744666X.2023.2244673 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 11 |b 08 |c 07 |h 1399-1406 | ||